A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis

Trial Profile

A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Iguratimod (Primary) ; Methotrexate (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Jiangsu Simcere Pharmaceutical
  • Most Recent Events

    • 22 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2017, as reported by ClinicalTrials.gov.
    • 12 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top